JBCHEPHARM · NSE
JBCHEPHARM
₹2,408.9
-3.87% (-₹97.1)
Prev. close
₹2,506
Volume
47,79,224
Delivery %
66.8%
As of
16 Jul 2026
Price history
Analyst sentiment
No analyst stances in this range
0 analyst stances · last 90 days · one per analyst
Try a wider range.
Explore by date range →Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on J B Chemicals and Pharmaceuticals, recommending a buy at ₹1821.70 with a target of ₹1945 and a stop loss at ₹…” | Sumeet BagadiaChoice Equity Broking | J.B.CHEMICALS & PHARMACEUTICAL | HIT | |
| “Bullish on J B Chemicals and Pharmaceuticals, recommending a buy at ₹1813 with a target of ₹1940 and a stop loss at ₹175…” | Sumeet BagadiaChoice Equity Broking | J B Chemicals and Pharmaceuticals Ltd | MISS | |
| “Bullish on JB Chemicals & Pharmaceuticals (JBCHEPHARMA), recommending a buy at current market price and on dips to ₹1,58…” | Raja VenkatramanNeoTrader | JB Chemicals & Pharmaceuticals Ltd | PENDING | |
| “Maintains a 'buy' call on J B Chemicals & Pharmaceuticals with a target price of ₹2,225 within a year. The brokerage bel…” | JM Financial AnalysisJM Financial Institutional Securities | J B Chemicals & Pharmaceuticals Ltd | PENDING | |
| “Bullish on J B Chemicals and Pharmaceuticals, recommending a buy at ₹1653.75 with a target of ₹1770 and a stop loss at ₹…” | Sumeet BagadiaChoice Equity Broking | J B Chemicals and Pharmaceuticals Ltd | PENDING | |
| “Upgraded J B Chemicals & Pharmaceuticals to 'ADD' from 'HOLD' with a revised target price of ₹1,815 (previously ₹1,870).…” | ICICI Securities AnalysisICICI Securities | J B Chemicals & Pharmaceuticals Ltd | PENDING |
Fundamentals
About JBCHEPHARM
J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company's API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; and nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dosage forms, such as tablets, capsules, liquids, gels, lozenges, creams, injectables, powder, cold rubs, eye drops, and troches; and soft-centered, powder, medicated, and herbal lozenges, as well as various pharmaceutical dosage forms. In addition, the company offers a range of contrast media products, including x-ray, magnetic resonance imaging (MRI), and ultrasound scanners; and contract manufacturing services. It provides its products to gastroenterology, anti-infectives, wound care, neonatology and pediatrics, genecology, dental, vitamins and minerals, hypertension, diabetes, nephrology, respiratory, pain-analgesic, dermatology, antivirals, lozenges, and contrast media and radio diagnostic therapeutic areas. J. B. Chemicals & Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Mumbai, India.
Details
Key stats
Market cap
₹38,792.59 Cr
P/E ratio (TTM)
54.2
EPS (TTM)
₹44.56
Beta (5Y monthly)
0.04
Shares float
8.16 Cr
EPS · quarter ended Mar 2026
₹6.32
Financial Performance
01 · Financials
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹2,042.52 Cr | ₹2,424.24 Cr | ₹3,116.51 Cr | ₹3,447.67 Cr | ₹3,862.04 Cr | ₹4,076.20 Cr | |
EBITDA | ₹672.79 Cr | ₹582.68 Cr | ₹705.05 Cr | ₹933.48 Cr | ₹1,069.12 Cr | ₹1,140.28 Cr |
| ₹448.52 Cr | ₹386.04 Cr | ₹409.84 Cr | ₹552.63 Cr | ₹659.58 Cr | ₹709.47 Cr | |
Diluted EPS | — | ₹24.91 | ₹26.17 | ₹34.85 | ₹41.56 | — |
Depreciation & amortisation, Pretax income, Tax provision, Interest expense, Diluted EPS have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹3,553.87 Cr | ₹3,994.13 Cr | ₹4,273.78 Cr | ₹4,968.65 Cr | |
| — | — | ₹572.45 Cr | ₹377.66 Cr | ₹27.89 Cr | ₹3.59 Cr | |
Stockholders' equity | — | — | ₹2,480.35 Cr | ₹2,923.33 Cr | ₹3,433.32 Cr | ₹4,159.22 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, Total debt, Long-term debt, Current (short-term) debt, Others, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹625.61 Cr | ₹800.61 Cr | ₹902.45 Cr | ₹703.92 Cr | |
Investing cash flow | — | — | ₹-961.79 Cr | ₹-403.83 Cr | ₹-295.90 Cr | ₹-585.88 Cr |
| — | — | ₹356.54 Cr | ₹-385.49 Cr | ₹-579.67 Cr | ₹-123.10 Cr | |
Capital expenditure | — | — | ₹-764.95 Cr | ₹-261.37 Cr | ₹-120.31 Cr | ₹-83.19 Cr |
End cash position | — | — | ₹76.93 Cr | ₹88.22 Cr | ₹115.09 Cr | ₹110.18 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Dividends paid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
Index membership
1 index